EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Other Sources: 13

Galactooligosaccharides (GOS)

Also called: GOS, galacto-oligosaccharides, transgalactooligosaccharides, trans-galactooligosaccharides

Galactooligosaccharides (GOS, also called transgalactooligosaccharides) are oligosaccharides studied as prebiotics. Health Canada accepts preparations with a degree of polymerization of 2–9 (mostly 3–5) and notes GOS products may contain small amounts of lactose and/or sugar/glucose.

Category
Other
Forms
Transgalactooligosaccharides (GOS) preparations, DP 2–9 with the majority DP 3–5 (Health Canada specification)
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. This entry cites 10 randomized placebo-controlled trials of GOS alone [5]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

6 topics studied3 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Galactooligosaccharides (GOS) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Galactooligosaccharides (GOS), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Fecal bifidobacteria in older adultsCIn a double-blind crossover RCT in 40 adults aged 65–80, 5.5 g/day GOS for 10 weeks increased bifidobacteria and bacteroides versus maltodextrin placebo, with changes in some immune markers. [2]
Symptoms of irritable bowel syndrome (IBS)CIn a 12-week randomized controlled trial in 44 patients with IBS, 3.5 g/day trans-galactooligosaccharide improved stool consistency, flatulence, bloating and global assessment, and 7 g/day improved global assessment and anxiety scores; placebo had no effect. [3]
Functional constipationCIn a 4-week double-blind RCT in 63 patients meeting Rome IV criteria (34 GOS, 29 placebo), GOS improved daily bowel movements and stool shape versus placebo. [4]
Lactose intolerance symptomsBIn a 30-day double-blind RCT in 377 patients with lactose intolerance, 40% given the purified GOS RP-G28 had a 4-point or greater symptom-score reduction or no symptoms, versus 26% on placebo (P = 0.016). [5]
Insulin sensitivity in prediabetesCIn a 12-week double-blind RCT in 44 overweight or obese prediabetic adults, 15 g/day GOS did not improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, although it increased Bifidobacterium. [6]
Trait anxiety in young womenCIn a 28-day double-blind RCT in 83 healthy females aged 17–25, trait anxiety did not differ between GOS and placebo at the end of supplementation; GOS transiently increased Bifidobacterium. [7]

Main constituents: Galactooligosaccharides (transgalactooligosaccharides), DP 2–9, majority DP 3–5 [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Studied in trials: 5.5 g or 11 g/day for 3 weeks in 132 adults with self-reported constipation; 11 g/day increased stool frequency versus control only in subgroups (3 or fewer bowel movements a week at baseline, or age 35 or older). [8]
  • Studied in trials: 0, 2.5 or 5.0 g/day for 8 weeks in 427 university students during exams; GOS lowered several gastrointestinal symptom scores. [9]
  • Studied in trials: 5.5 g/day for 12 weeks versus maltodextrin in 29 men with type 2 diabetes; no significant effects on clinical outcomes or bacterial abundances. [10]
  • Studied in trials: 2.75 g/day for 2 weeks (crossover) in 83 adults with bloating, abdominal pain or flatulence; symptom scores fell versus placebo, with no effect on bowel movements, stool consistency, quality of life or mood. [11]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    1 listed

    Other medications or health products

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    1 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Canada (Health Canada Prebiotics monograph, April 24, 2026), adults 18 years and older: transgalactooligosaccharides 2–15 g/day for prebiotic uses …

    Details and sources
  • In the 63-patient constipation RCT, no significant adverse drug reactions were identified in any indicator except pulse rate. [4]
  • In the 377-patient lactose-intolerance RCT, the authors reported the purified GOS was safe and well tolerated over 30 days. [5]
  • Health Canada requires GOS products to say to stop use if hypersensitivity/allergy occurs; GOS that has contacted milk needs allergen labeling, and products may state they contain small amounts of lactose and/or sugar/glucose. [1]
Interactions

Interactions

Known interactions of Galactooligosaccharides (GOS)
WithWhat happens
Other medications or health productsHealth Canada's Prebiotics monograph directs taking these products a few hours before or after other medications or health products, with at least 250 mL of liquid. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Health Canada accepts GOS preparations with DP 2–9 (majority 3–5); labeled amounts must represent the declared oligosaccharide content (dry basis), measured by validated methods such as HPLC, LC-MS or size exclusion chromatography. [1]
Regulation

Regulatory status

  • US: FDA lists galactooligosaccharide among non-digestible carbohydrates it intends to propose adding to the dietary fiber definition; until rulemaking is complete, FDA intends to exercise enforcement discretion to allow it in the dietary fiber declaration. [12]
  • US: FDA had no questions about GRAS Notice 236 for galacto-oligosaccharides in term infant formula and certain foods (closed July 28, 2008), the earliest of 15 such GOS-named notices with that response. These concern food uses. [13]
  • Canada: transgalactooligosaccharides are covered by Health Canada's Prebiotics monograph (April 24, 2026) for prebiotic and source-of-fiber uses in adults. [1]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Galactooligosaccharides (transgalactooligosaccharides), DP 2–9, majority DP 3–5 Polysaccharides (oligosaccharides) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 1 entry naming galacto-oligosaccharide (NDI 27 submitted 1998-03-19). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
  • GRAS: FDA's GRAS Notice Inventory lists 18 notices with galacto-oligosaccharides in the substance name (FDA had no questions for 15, including one combined with polydextrose and one for alpha-galacto-oligosaccharides; FDA ceased to evaluate 3 at the notifier's request). The earliest closed, GRN 236, closed July 28, 2008. GRAS notices concern food uses. [P3]
  • Dietary fiber: FDA lists galactooligosaccharide among non-digestible carbohydrates it intends to propose as dietary fiber and intends to exercise enforcement discretion for its declaration meanwhile. [P4]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of galactooligosaccharides was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P5]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of galactooligosaccharides (checked 2026-10-29). [P6]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Other medications or health products: Health Canada's Prebiotics monograph: take a few hours before or after taking other medications or health products. [P1]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]
  • GOS content and chain length (DP 2–9, majority 3–5) by a validated method, e.g. HPLC, LC-MS or size exclusion chromatography — Health Canada's specification for GOS; it states enzymatic-gravimetric methods are not generally suitable on their own for low-molecular-weight oligosaccharides. [P1]
  • Milk allergen and residual lactose/sugar disclosure — Health Canada requires allergen labeling if GOS has contacted milk and allows a statement that GOS products may contain small amounts of lactose and/or sugar/glucose. [P1]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Canada (Health Canada Prebiotics monograph, April 24, 2026), adults 18 years and older: transgalactooligosaccharides 2–15 g/day for prebiotic uses and 2–15 g/day for source-of-fiber uses; combined prebiotic ingredients must not exceed 15 g/day. [P1]

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Health Canada NNHPD. Natural health product monograph: Prebiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. FDA. GRAS Notice Inventory (downloaded export; inventory last updated 10/21/2026; downloaded 10/29/2026), 2026-10-21. hfpappexternal.fda.gov
  4. FDA. Questions and Answers on Dietary Fiber (content current as of 07/25/2024), 2024-07-25. fda.gov
  5. IARC Monographs. List of Classifications, Volumes 1–142 (list data dated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
  6. National Toxicology Program (NIEHS). Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  7. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/28/2026), 2026-10-28. ecfr.gov
Sources

Sources

  1. Health Canada NNHPD. Natural health product monograph: Prebiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  2. Vulevic J, et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr 2015;114(4):586-95 (PMID 26218845), 2015-08. pubmed.ncbi.nlm.nih.gov
  3. Silk DB, et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009;29(5):508-18 (PMID 19053980), 2009-03. pubmed.ncbi.nlm.nih.gov
  4. Lee JH, et al. Efficacy and safety of galacto-oligosaccharide in the treatment of functional constipation: randomized clinical trial. Food Funct 2024;15(12):6374-6382 (PMID 38787732), 2024-06. pubmed.ncbi.nlm.nih.gov
  5. Chey W, et al. Galacto-oligosaccharide RP-G28 improves multiple clinical outcomes in lactose-intolerant patients. Nutrients 2020;12(4) (PMID 32290344), 2020-04. pubmed.ncbi.nlm.nih.gov
  6. Canfora EE, et al. Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 2017;153(1):87-97.e3 (PMID 28396144), 2017-07. pubmed.ncbi.nlm.nih.gov
  7. Johnstone N, et al. A randomised controlled trial of the effects of galacto-oligosaccharides on the gut brain-axis of young females. Brain Behav Immun 2025;129:573-584 (PMID 40532960), 2025-10. pubmed.ncbi.nlm.nih.gov
  8. Schoemaker MH, et al. Prebiotic galacto-oligosaccharides impact stool frequency and fecal microbiota in self-reported constipated adults: a randomized clinical trial. Nutrients 2022;14(2) (PMID 35057489), 2022-01. pubmed.ncbi.nlm.nih.gov
  9. Hughes C, et al. Galactooligosaccharide supplementation reduces stress-induced gastrointestinal dysfunction and days of cold or flu: a randomized, double-blind, controlled trial in healthy university students. Am J Clin Nutr 2011;93(6):1305-11 (PMID 21525194), 2011-06. pubmed.ncbi.nlm.nih.gov
  10. Pedersen C, et al. Host-microbiome interactions in human type 2 diabetes following prebiotic fiber (galacto-oligosaccharide) intake. Br J Nutr 2016;116(11):1869-1877 (PMID 27974055), 2016-12. pubmed.ncbi.nlm.nih.gov
  11. Vulevic J, et al. Effect of a prebiotic galactooligosaccharide mixture (B-GOS) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence. Neurogastroenterol Motil 2018;30(11):e13440 (PMID 30109908), 2018-11. pubmed.ncbi.nlm.nih.gov
  12. FDA. Questions and Answers on Dietary Fiber (content current as of 07/25/2024), 2024-07-25. fda.gov
  13. FDA. GRAS Notice Inventory (downloaded export; inventory last updated 10/21/2026; downloaded 10/29/2026), 2026-10-21. hfpappexternal.fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.